December 9, 2019   How the use of anti-VEGF agents is evolving over time Anti-VEGF agents have ushered in a new era of treatment for retinal and choroidal neovascularization. Here’s what researchers have learned in determining how these agents have evolved over time, specifically regarding trends for U.S. Medicare Part B beneficiaries. Learn more ADVERTISEMENT   Myopia may prove beneficial in preventing DR development New research has shown that a longer axial length may prove protective of incident diabetic retinopathy. Find out ADVERTISEMENT   What AAO attendees learned from a single session devoted to diabetes At Retina Subspecialty Day during the 2019 AAO meeting, presentations as varied as artificial intelligence, news from the Diabetic Retinopathy Clinical Research Retina Network (DRCR.net), using OCT to predict visual outcomes, and how to manage patients with high-risk nonproliferative diabetic retinopathy without DME were among the highlights. Find out ADVERTISEMENT     RELATED ARTICLES AMD risk phenotypes targeted in direct-to-consumer genetic database Focusing the battle against dry AMD Guidelines for treating the diabetic eye patient Anti-VEGF injections + glaucoma: Surgeons must watch IOP elevation